Controlled Expression and Assembly of Human Group-C Rotavirus-like Particles for Creation of Rotavirus Diagnostic Assays and Improved Vaccine Formulations
This technology allows for the expression of the three major capsid proteins (VP2, VP6 and VP7) of GpC rotavirus by recombinant baculovirus and assembly of virus-like particles (2-6-7 and/or 6-7) within insect cells. Further, this CDC generated technology allows for the large-scale access to GpC rotavirus antigens, previously infeasible, and will permit use of these novel virus-like particles for the development of rotavirus diagnostic assays and improved vaccine formulations.
- Development or improvement of rotavirus vaccines
- Rotavirus vaccine composition research
- Childhood illness vaccination programs and rotavirus monitoring endeavors
- Development of novel rotavirus diagnostic tools
- Permits large-scale production of Group-C rotavirus antigens, previously impractical
- Produced virus-like particles/antigens can be used for rotavirus vaccines, other immunogenic uses and/or sero-diagnostic assay development
- Diagnostic tools for Group-C rotavirus are currently unavailable; this technology fulfills an unmet need for accurate assessment of the Group-C rotaviral global health burden